Zhejiang Medicine Co Ltd

Zhejiang Medicine released its 2026 interim report, with total operating revenue of 4.386 billion yuan and net profit attributable to the parent company of 606 million yuan, down 9.99% from the same period last year. Net cash inflow from operating activities was 452 million yuan, down 43.34% year on year. The company's asset-liability ratio was 18.48%, gross margin was 37.15%, ROE was 5.20%, and diluted earnings per share was 0.63 yuan. The number of shareholders was 55,600, and the top ten shareholders held 49.01% of the total share capital.

Zhejiang Medicine released its 2026 semi-annual report, achieving operating revenue of 4.386 billion yuan, up 1.46% year on year; net profit attributable to shareholders of the listed company was 606 million yuan, down 9.99% year on year. The company's second-quarter net profit was 319 million yuan, and first-quarter net profit was 287 million yuan, meaning second-quarter net profit rose 11% quarter on quarter.

Zhejiang Medicine disclosed its 2026 semi-annual report. In the first half, it achieved operating revenue of 4.386 billion yuan, up 1.46% year on year. Net profit attributable to shareholders of the listed company was 606 million yuan, down 9.99% year on year.